Arrowhead Research
ARWR
About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Employees: 609
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
53% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 38
27% more capital invested
Capital invested by funds: $1.32B [Q1] → $1.67B (+$353M) [Q2]
22% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 79
7% more funds holding
Funds holding: 261 [Q1] → 279 (+18) [Q2]
1.28% more ownership
Funds ownership: 75.34% [Q1] → 76.62% (+1.28%) [Q2]
22% less call options, than puts
Call options by funds: $8.24M | Put options by funds: $10.6M
40% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Patrick R. Trucchio
|
$80
|
Buy
Reiterated
|
2 Sep 2025 |
|
Chardan Capital
Keay Nakae
|
$60
|
Buy
Maintained
|
11 Aug 2025 |
|
RBC Capital
Luca Issi
|
$38
|
Outperform
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 12 articles about ARWR published over the past 30 days
